/A randomized, controlled, multicenter, phase 3 study of vusolimogene oderparepvec combined with nivolumab vs treatment of physician’s choice in patients with advanced melanoma that has progressed on anti–PD-1 and anti–CTLA-4 therapy (IGNYTE-3).

Citation Map

Citing

Cited By

The articles shown here are a subset.See the full list of articles below.

Citing (0)

Sort By:

Data not found

Cited By (0)

Sort By: